Goldman Sachs’s Frazier Lifesciences Acquisition Corp Warrant FLACW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-31,806
Closed -$24K – 6566
2022
Q3
$24K Sell
31,806
-134,500
-81% -$85.4K ﹤0.01% 5909
2022
Q2
$13K Sell
166,306
-360
-0.2% -$63 ﹤0.01% 6243
2022
Q1
$29K Buy
+166,666
New +$72.4K ﹤0.01% 6364

Goldman Sachs's FLACW Position: Q4 2022 in Review

Goldman Sachs sold out of Frazier Lifesciences Acquisition Corp Warrant (FLACW) in Q4 2022, closing a stake of 31,806 shares — an estimated $24K sold.

Goldman Sachs first reported a position in FLACW in Q1 2022 and held it in 3 quarters. The position peaked at $29K in Q1 2022. 0 funds tracked by Wall St. Rank hold FLACW as of Q4 2022.

  • Goldman Sachs reported no remaining Frazier Lifesciences Acquisition Corp Warrant position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 31,806 Frazier Lifesciences Acquisition Corp Warrant shares in Q4 2022, an estimated $24K.
  • Goldman Sachs first reported a position in Frazier Lifesciences Acquisition Corp Warrant in Q1 2022 and held it in 3 quarters.
  • Goldman Sachs's Frazier Lifesciences Acquisition Corp Warrant position peaked at $29K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corp Warrant as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.